Brief: Ginkgo Bio, SaponiQx Awarded MCDC Contract To Discover And Manufacture Next-Generation Vaccine Adjuvants
15/02/2024 12:46
Feb 15 (Reuters) - Ginkgo Bioworks Holdings Inc DNA.N :
* GINKGO BIOWORKS AND SAPONIQX AWARDED MCDC CONTRACT TO
DISCOVER
AND MANUFACTURE NEXT-GENERATION VACCINE ADJUVANTS USING
GENERATIVE MOLECULAR DESIGN
* GINKGO BIOWORKS - 5-YEAR CONTRACT TOTALING UP TO $31
MILLION
INCLUDING PROGRAM OPTIONS
Source text for Eikon: ID:nPn6wG2BKa
Further company coverage: DNA.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Agenus
See all newsBrief: Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income